

## Clinical Requirements for Closed-Loop Control Systems

William L. Clarke, M.D.,<sup>1</sup> and Eric Renard, M.D., Ph.D.<sup>2</sup>

### Abstract

Closed-loop (CL) therapy systems should be safe, efficacious, and easily manageable for type 1 diabetes mellitus patient use. For the first two clinical requirements, noninferiority and superiority criteria must be determined based on current conventional and intensive therapy outcomes. Current frequencies of hypoglycemia and diabetic ketoacidosis are reviewed and safety expectations for CL therapy systems are proposed. Glycosylated hemoglobin levels lower than current American Diabetes Association recommendations for different age groups are proposed as superiority criteria. Measures of glycemic variability are described and the recording of blood glucose levels as percentages within, above, and below a target range are suggested as reasonable alternatives to sophisticated statistical analyses. It is also suggested that Diabetes Quality of Life and Fear of Hypoglycemia surveys should be used to track psychobehavioral outcomes.

Manageability requirements for safe and effective clinical management of CL systems are worth being underscored. The weakest part of the infusion system remains the catheter, which is exposed to variable and under-delivery incidents. Detection methods are needed to warn both the system and the patient about altered insulin delivery, including internal pressure and flow alarms. Glucose monitor sensor accuracy is another requirement; it includes the definition of conditions that lead to capillary glucose measurement, eventually followed by sensor recalibration or replacement. The crucial clinical requirement will be a thorough definition of the situations when the patient needs to move from CL to manual management of insulin delivery, or inversely can switch back to CL after a requested interruption. Instructions about these actions will constitute a major part of the education process of the patients before using CL systems and contribute to the manageability of these systems.

*J Diabetes Sci Technol 2012;6(2):444-452*

**Author Affiliations:** <sup>1</sup>Division of Pediatric Endocrinology, Department of Pediatrics, University of Virginia Health Sciences Center, Charlottesville, Virginia; and <sup>2</sup>Department of Endocrinology, Diabetes, Nutrition, Clinical Investigation Center INSERM 1001, University of Montpellier, Montpellier, France

**Abbreviations:** (BG) blood glucose, (BGRI) blood glucose risk index, (CGM) continuous glucose monitor, (CL) closed loop, (CSII) continuous subcutaneous insulin infusion, (DCCT) Diabetes Control and Complications Trial, (DKA) diabetic ketoacidosis, (FDA) Food and Drug Administration, (HbA1c) glycosylated hemoglobin, (HBGI) high blood glucose index, (JDRF) Juvenile Diabetes Research Foundation, (LBGI) low blood glucose index, (MDI) multiple daily injection, (SBGM) self-blood glucose monitoring, (SD) standard deviation, (SH) severe hypoglycemia, (STAR 3) sensor-augmented pump therapy for A1C reduction, (T1DM) type 1 diabetes mellitus

**Keywords:** closed-loop control, diabetic ketoacidosis, diabetes quality of life, efficacy, fear of hypoglycemia, glucose monitoring, glycemic variability, glycosylated hemoglobin, hypoglycemia, insulin delivery, management of insulin infusion, noninferiority, safety, superiority

**Corresponding Author:** William L. Clarke, M.D., Division of Pediatric Endocrinology, Department of Pediatrics, University of Virginia Health Sciences Center, Charlottesville, VA 22908; email address [wlc@virginia.edu](mailto:wlc@virginia.edu)